Introduction to Secondary Hepatic

Furthermore, three randomized clinical trials have shown that LLS performed for primary or secondary hepatic malignancies does not compromise oncologic outcomes compared again to open hepatectomy (4-6).

TARE is a commonly used treatment for unresectable primary or secondary hepatic malignancies and has led to improved survival rates and increased success rates in downstaging patients before liver resection or transplantation.

ABSTRACT Objectives: The aim of this study was to assess the profile of secondary hepatic injury (SHI), to determine risk factors and to evaluate its impact on prognosis of pediatric intensive care patients.

As secondary hepatic disorders may occur due to postprandial hyperglycemia, the treatment's ultimate goal is to prevent both hypoglycemia and hyperglycemia.

Twenty-seven RFA ablations for either primary or secondary hepatic tumors were included.

Remarkably, while inhibiting ceramide synthesis exerted no influences on TREM2-dependent ATM remodeling, inflammation, or lipid load, it restored insulin tolerance, reversing adipose hypertrophy and secondary hepatic steatosis of TREM2-deficient animals.

This paper focused on evaluating the effect of TLR4-MyD88-NF-κB signaling pathway in the progression of secondary hepatic injury and fibrosis in hepatolithiasis.

Here, we evaluate pre-interventional EVs as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies.

CONCLUSION ADC values seem to represent an additional marker for treatment response evaluation after TARE in patients with secondary hepatic NET.

Here, we evaluate MIF serum concentrations as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies.

Background: Liver resection represents the first curative treatment to treat primary and secondary hepatic tumors.

MATERIAL AND METHODS Data from patients with primary or secondary hepatic malignancies treated between 2004 and 2018 with MRI-guided percutaneous thermoablation of hepatic recurrence after prior hepatic resection were retrospectively analyzed.

Purpose Transarterial radioembolization (TARE) with yttrium-90 ( 90 Y) microspheres is a liver-directed treatment for primary and secondary hepatic malignancies.

Background & Aims Non-alcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis in the absence of other causes of secondary hepatic fat accumulation, and is usually associated with visceral, metabolically active obesity.

Secondary hepatic lymphoma is defined based on distant involvement, and it typically presents as diffuse infiltration, as in this case.

Emulators of mass-forming cholangiocarcinoma include other primary and secondary hepatic malignancies, benign tumors and tumor-like mimics such as abscess, hemangioma and confluent hepatic fibrosis.

Transarterial embolisation, such as transarterial chemoembolization (TACE) or selective internal radiation therapy (SIRT) are well established, usually palliatively intended treatment options for primary and secondary hepatic malignancies.

It would have been beneficial for readers if we had clarified our distribution of primary and secondary hepatic malignancy.

The majority of these procedures were performed for hepatic alveolar echinococcosis (69%) followed by primary and secondary hepatic malignancies.

More importantly, in the rat model of secondary hepatic alveolar echinococcosis, the anti-hepatic alveolar echinococcosis effect of TABZ-HES-H was 3.

Liver surgery and transplantation currently represent the only curative treatment options for primary and secondary hepatic malignancies.

Transarterial radioembolization of primary and secondary hepatic malignancies utilizing yttrium-90 microspheres is a commonly performed treatment by interventional radiologists.

This is important for the readers as the outcomes after hepatic resection in primary and secondary hepatic malignancies have shown to differ greatly [3, 4].

Thermal ablations are becoming an increasingly common alternative treatment to surgery in patients with primary and secondary hepatic tumors.

Secondary hepatic venous pressure gradient was also measured.

Radioembolization with Yttrium-90 (Y90) has been proven safe and effective for the treatment of primary and secondary hepatic malignancies.

Thus, the patient was diagnosed with disseminated Bartonella henselae infection, and secondary hepatic and splenic micro-abscesses, based on the combination of the epidemiological, clinical, imaging and serological criteria.

While the most compelling levels of evidence for the use of Yttrium-90 (90Y) radioembolization are in patients with hepatocellular carcinoma and hepatic metastases from colorectal cancer, a growing body of literature supports its use in other primary and secondary hepatic malignancies.

Percutaneous thermal ablation of hepatic tumors continues to play an integral role in the treatment of early-stage primary or secondary hepatic malignancies.

We herein review the methodologies for measuring tumor response and survival, among patients treated with RFA for primary and secondary hepatic malignancies.

On the contrary, relatively scarce data specifically focusing on secondary hepatic malignancies is available.

Moreover, in the van Dijk study, a composite host phenotype consisting of adverse BC and SI was shown to have an additive and synergistic deleterious effect on survival (HR of death >4) and was also statistically independent of the Fong clinical prognostic score (a 5-point score that assesses nodal status of the primary tumour, the disease-free interval, the size and number of secondary hepatic tumours, and the preoperative serum CEA level).

PURPOSE To assess the infection rate after eliminating postprocedural antibiotics in patients undergoing hepatic artery embolization (HAE) for primary and secondary hepatic malignancies.

According to the current criteria in the literature, our patient had aspects indicative of primary and secondary hepatic lymphoma.

CONCLUSION AlbCre+Cc1fl/fl mutants provide an in vivo demonstration of the key role of impaired hepatic insulin clearance and hyperinsulinemia in the pathogenesis of secondary hepatic insulin resistance independently of lipolysis.

Blood glucose levels following insulin therapy were not correlated with the length of PICU stay, total length of stay, mortality, secondary coma, or secondary hepatic or renal dysfunction in the three groups.

Primary hepatic lymphoma is quite rare, accounting for less than 1% of all cases of non-Hodgkin lymphoma, whereas secondary hepatic lymphoma affects nearly half of such cases.

MATERIALS AND METHODS Between January 2012 and January 2016, 85 patients underwent 109 SIRT treatments for either primary or secondary hepatic malignancies.

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by hepatic steatosis in the absence of other causes, such as chronic alcohol consumption, that cause secondary hepatic fat accumulation.

MethodsTwenty four patients (13 women, 11 men) scheduled for hemihepatectomy due to histologically proven primary or secondary hepatic malignancies were included in our study.

Introduction Liver resection is the only curative treatment for primary and secondary hepatic tumours.

These infections can be primarily related to the liver or can include secondary hepatic involvement.

TPVE was performed on 18 patients before right hepatic resection for both primary and secondary hepatic malignancies (10 hepatocellular carcinomas, 4 cases of colorectal liver metastasis, and 4 cholangiocarcinomas).

Curative options for the treatment of primary or secondary hepatic malignancies are transplant and surgical resection.

0 cm radius of the ablation zone were assessed after IRE of 112 hepatic lesions (74 primary, 38 secondary hepatic malignancies) by pre-interventional and post-interventional (1–3 days, 6 weeks and 3 months after IRE) contrast-enhanced magnetic resonance imaging.

Secondary hepatic neoplasms refer to tumors that metastasize to the liver, a spectrum that includes carcinomas, neuroendocrine cancers, sarcomas, and gastrointestinal stromal tumors.

G1 also exhibited higher rates of primary and secondary hepatic malignancies (G1: n = 62; 92.